About: Delcath Systems

Facets (new session)
Description
Metadata
Settings
- Rule:
- Inverse Functional Properties:
- "Same As":

About: Delcath Systems Goto Sponge NotDistinct Permalink

An Entity of Type : yago:SocialGroup107950920, within Data Space : dbpedia.org associated with source document(s)
QRcode icon

http://dbpedia.org/describe/?url=http%3A%2F%2Fdbpedia.org%2Fresource%2FDelcath_Systems

Delcath Systems, Inc. (NASDAQ: DCTH) is a publicly traded specialty pharmaceutical and medical device company that develops percutaneous perfusion technologies for the targeted administration of high-dose chemotherapeutic agents to specific organs or regions of the body. Based in Queensbury, New York, the company has an intellectual property portfolio consisting of 28 patents worldwide. Delcath's Percutaneous Hepatic Perfusion (PHP) is currently undergoing Phase II and Phase III trials against tumors in the liver. Delcath has a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute and has received Fast Track and a Special Protocol Assessment from the Food and Drug Administration for its use of melphalan in treating unresectable liver tumors. PHP, also kn

Attributes	Values
rdf:type	Thing schema:Organization dul:Agent dul:SocialPerson agent wikidata:Q24229398 Organization yago:WikicatCancerOrganizations yago:WikicatCompaniesBasedInNewYorkCity yago:WikicatCompaniesListedOnNASDAQ yago:Abstraction100002137 yago:Company108058098 yago:Group100031264 yago:Institution108053576 yago:Organization108008335 yago:WikicatHealthCareCompaniesOfTheUnitedStates yago:YagoLegalActor yago:YagoLegalActorGeo yago:YagoPermanentlyLocatedEntity organisation yago:SocialGroup107950920
rdfs:label	Delcath Systems (en)
rdfs:comment	Delcath Systems, Inc. (NASDAQ: DCTH) is a publicly traded specialty pharmaceutical and medical device company that develops percutaneous perfusion technologies for the targeted administration of high-dose chemotherapeutic agents to specific organs or regions of the body. Based in Queensbury, New York, the company has an intellectual property portfolio consisting of 28 patents worldwide. Delcath's Percutaneous Hepatic Perfusion (PHP) is currently undergoing Phase II and Phase III trials against tumors in the liver. Delcath has a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute and has received Fast Track and a Special Protocol Assessment from the Food and Drug Administration for its use of melphalan in treating unresectable liver tumors. PHP, also kn (en)
foaf:name	Delcath Systems (en)
name	Delcath Systems (en)
dcterms:subject	Hepatology organizations Companies listed on the Nasdaq Companies based in New York City Cancer organizations based in the United States Health care companies based in New York (state) Specialty drugs
Wikipage page ID	12293417 (xsd:integer)
Wikipage revision ID	1082390783 (xsd:integer)
Link from a Wikipage to another Wikipage	Cancers Capecitabine Hepatology organizations Queensbury, New York Patents University of Pittsburgh Medical Center University of Texas Medical Branch Intellectual property Intravenous therapy Route of administration University of Maryland Medical Center Midtown Campus Tumors Companies listed on the Nasdaq Melanoma Melphalan Liver Clinical trial Percutaneous Percutaneous hepatic perfusion Companies based in New York City Busulfan Wilmington, Delaware H. Lee Moffitt Cancer Center & Research Institute Albany Medical Center Food and Drug Administration Segmental resection Hepatocellular carcinoma Adenocarcinomas Cancer organizations based in the United States Health care companies based in New York (state) Specialty drugs Swedish Health Services Cooperative Research and Development Agreement FDA Fast Track National Cancer Institute Neuroendocrine tumor Morristown Medical Center Metastatic Chemotherapeutic
sameAs	Delcath Systems Delcath Systems Delcath Systems Delcath Systems
dbp:wikiPageUsesTemplate	dbt:Authority_control dbt:Infobox_organization dbt:Reflist dbt:URL dbt:Med-company-stub dbt:Oncology-stub
formation	1988 (xsd:integer)
headquarters	Wilmington, Delaware
purpose	Specialty pharmaceutical (en)
services	Pharmaceutical and medical device company focused on oncology (en)
has abstract	Delcath Systems, Inc. (NASDAQ: DCTH) is a publicly traded specialty pharmaceutical and medical device company that develops percutaneous perfusion technologies for the targeted administration of high-dose chemotherapeutic agents to specific organs or regions of the body. Based in Queensbury, New York, the company has an intellectual property portfolio consisting of 28 patents worldwide. Delcath's Percutaneous Hepatic Perfusion (PHP) is currently undergoing Phase II and Phase III trials against tumors in the liver. Delcath has a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute and has received Fast Track and a Special Protocol Assessment from the Food and Drug Administration for its use of melphalan in treating unresectable liver tumors. PHP, also known as the Delcath System, is tested for the treatment of metastatic melanoma in the liver and for primary liver cancer and metastatic hepatic malignancies from neuroendocrine cancers and adenocarcinomas, as well as patients with melanoma who previously received isolated perfusion. Chemotherapy is usually delivered intravenously, although a number of agents can be administered orally (e.g. specialty drugs, melphalan (trade name Alkeran), busulfan, capecitabine). (en)
skos:closeMatch	http://www.grid.ac/institutes/grid.476204.3
prov:wasDerivedFrom	wikipedia-en:Delcath_Systems?oldid=1082390783&ns=0
page length (characters) of wiki page	4370 (xsd:nonNegativeInteger)
purpose	Specialty pharmaceutical
headquarter	Wilmington, Delaware
foaf:isPrimaryTopicOf	wikipedia-en:Delcath_Systems
is Link from a Wikipage to another Wikipage of	Delcath Delcath Systems, Inc. Percutaneous hepatic perfusion
is Wikipage redirect of	Delcath Delcath Systems, Inc.
is foaf:primaryTopic of	wikipedia-en:Delcath_Systems

Faceted Search & Find service v1.17_git139 as of Feb 29 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 08.03.3330 as of Mar 19 2024, on Linux (x86_64-generic-linux-glibc212), Single-Server Edition (378 GB total memory, 62 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software